Baird lowered the firm’s price target on Medtronic (MDT) to $92 from $94 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results which showed underlying fundamentals improving while the diabetes spinoff likely caps its upside.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic Reports Strong FY25 Results and Dividend Increase
- Medtronic’s Strong Financial Performance and Promising Growth Outlook Justify Buy Rating
- Medtronic’s Mixed Outlook: Hold Rating Amid Profitability Concerns and Strategic Initiatives
- Medtronic sees Q1 EPS $1.22-$1.24, consensus $1.32
- MDT Earnings: Medtronic Stock Slips Despite Earnings Beat